Published in Muscle Nerve on May 01, 2012
Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome. J Neuroimmune Pharmacol (2012) 0.87
Recent Advances and Review on Treatment of Stiff Person Syndrome in Adults and Pediatric Patients. Cureus (2015) 0.84
Presynaptic neuromuscular transmission defect in the stiff person syndrome. BMC Neurol (2016) 0.75
Deep Venous Thrombosis with Pulmonary Embolism Related to IVIg Treatment: A Case Report and Literature Review. Case Rep Med (2015) 0.75
Anti-glutamic acid decarboxylase antibody positive neurological syndromes. Neurosciences (Riyadh) (2016) 0.75
Stiff person syndrome and rituximab. Muscle Nerve (2012) 0.75
Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature (1990) 6.71
Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol (1999) 5.56
Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin (1956) 4.77
Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain (2008) 3.51
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med (1990) 3.21
Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol (1996) 3.16
Corelease of two fast neurotransmitters at a central synapse. Science (1998) 3.06
High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med (2001) 3.04
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
TMS and drugs. Clin Neurophysiol (2004) 2.52
Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology (2008) 2.48
Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med (1988) 2.44
Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40
Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain (2010) 2.35
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet (2005) 2.20
The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology (2000) 2.20
Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol (2002) 2.17
Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of ranvier in brain and around T tubules in skeletal muscle. J Cell Biol (1997) 2.04
Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J Neurosci (2000) 2.04
Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol (1999) 2.03
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol (2001) 1.90
The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci (1998) 1.72
Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72
Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A (1983) 1.71
Stiff-man syndrome updated. Mayo Clin Proc (1989) 1.71
The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med (1993) 1.71
GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J Neurochem (2006) 1.66
Dextromethorphan decreases the excitability of the human motor cortex. Neurology (1998) 1.66
Neuromyotonia. Clin Neurophysiol (2006) 1.65
The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med (1999) 1.64
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (2006) 1.62
High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun (2007) 1.60
Stiff man syndrome and related conditions. Mov Disord (2002) 1.60
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain (2004) 1.59
The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol (2005) 1.57
The stiff man and stiff man plus syndromes. J Neurol (1999) 1.56
Stiff man syndrome: neurophysiological findings in eight patients. J Neurol (1995) 1.53
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology (2001) 1.51
Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol (1998) 1.46
Autoimmunity in stiff-Man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161. FEBS Lett (1994) 1.41
Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology (2004) 1.41
Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol (2007) 1.40
Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol (1994) 1.37
Origin of facilitation of motor-evoked potentials after paired magnetic stimulation: direct recording of epidural activity in conscious humans. J Neurophysiol (2006) 1.37
Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med (1994) 1.36
Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol (2009) 1.36
Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord. J Comp Neurol (1997) 1.36
Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol (2005) 1.35
Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest (2001) 1.35
Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med (1993) 1.34
Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol (1983) 1.33
Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol (1996) 1.31
Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology (2000) 1.28
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) (2003) 1.27
Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve (2006) 1.27
Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci (1991) 1.26
The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry (1984) 1.26
Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans. Exp Brain Res (1996) 1.24
Association of GAD-65, but not of GAD-67, with the Golgi complex of transfected Chinese hamster ovary cells mediated by the N-terminal region. Proc Natl Acad Sci U S A (1993) 1.22
Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron (2000) 1.21
Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry (2005) 1.20
A new and effective drug in the treatment of the stiff-man syndrome: preliminary report. Proc Staff Meet Mayo Clin (1963) 1.20
Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology (1998) 1.17
Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol (2004) 1.16
Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J Clin Endocrinol Metab (2005) 1.16
Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology (2004) 1.15
Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry (2001) 1.14
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther (2004) 1.13
Plasma exchange and immunosuppression in the stiff man syndrome. Lancet (1989) 1.12
Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med (1989) 1.11
Stiff-man syndrome. Two patients treated with diazepam. JAMA (1966) 1.08
Intracortical inhibition and facilitation in the conventional paired TMS paradigm. Electroencephalogr Clin Neurophysiol Suppl (1999) 1.08
Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol (2010) 1.07
Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology (2004) 1.05
Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology (1998) 1.04
Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci (2009) 1.04
Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry (1999) 1.03
Invited article: inhibition of B cell functions: implications for neurology. Neurology (2008) 1.03
Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol (1999) 1.03
Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol (1993) 1.03
Stiff-man syndrome. Semin Neurol (1994) 1.01
Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord (2006) 1.00
Stiff-person syndrome following West Nile fever. Arch Neurol (2004) 0.98
Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain (2006) 0.98
Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol (1996) 0.98
Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med (1998) 0.97
Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum (1994) 0.97
The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med (1996) 0.97
Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci (2010) 0.96
Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology (2004) 0.96
Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes (1995) 0.96
Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry (2007) 0.96
Conductance of recombinant GABA (A) channels is increased in cells co-expressing GABA(A) receptor-associated protein. J Biol Chem (2004) 0.95
Motor cortex excitability in stiff-person syndrome. Brain (2000) 0.95
Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med (2010) 0.95
Neuropharmacological investigations in the stiff-man syndrome. J Neurol (1986) 0.94
Mutant dynactin in motor neuron disease. Nat Genet (2003) 5.28
Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol (2002) 2.67
Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol (2005) 2.34
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve (2003) 1.51
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.21
A high performance sensorimotor beta rhythm-based brain-computer interface associated with human natural motor behavior. J Neural Eng (2007) 1.18
Reliability of fiber tracking measurements in diffusion tensor imaging for longitudinal study. Neuroimage (2009) 1.15
White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain (2011) 1.15
Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One (2012) 1.13
Recommendations of the Neurolaryngology Study Group on laryngeal electromyography. Otolaryngol Head Neck Surg (2009) 1.01
Do F-wave measurements detect changes in motor neuron excitability? Muscle Nerve (2004) 0.99
Patterned sensory stimulation induces plasticity in reciprocal ia inhibition in humans. J Neurosci (2003) 0.98
Towards a user-friendly brain-computer interface: initial tests in ALS and PLS patients. Clin Neurophysiol (2010) 0.96
Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle Nerve (2009) 0.93
Movement-related cortical potentials in primary lateral sclerosis. Ann Neurol (2006) 0.88
Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve (2007) 0.88
Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin (2012) 0.87
Usage of support services in primary lateral sclerosis. Amyotroph Lateral Scler (2009) 0.84
Imaging findings associated with cognitive performance in primary lateral sclerosis and amyotrophic lateral sclerosis. Dement Geriatr Cogn Dis Extra (2013) 0.83
A pilot study of the prevalence of psychiatric disorders in PLS and ALS. Amyotroph Lateral Scler (2010) 0.81
Increased brainstem excitability in stiff-person syndrome. Neurology (2002) 0.78
Disease spread through contiguity and axonal tracts in primary lateral sclerosis. Muscle Nerve (2014) 0.75
Physiology of the motor cortex in polio survivors. Muscle Nerve (2008) 0.75
Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron (2014) 0.75